About OXGENE
OXGENE is a company based in Oxford (United Kingdom) founded in 2011 was acquired by WuXi AppTec in March 2021.. OXGENE has raised $28.09 million across 13 funding rounds from investors including Gov.uk, WuXi AppTec and Canaccord Genuity Group. The company has 102 employees as of December 31, 2021. OXGENE operates in a competitive market with competitors including Inscripta, Poseida Therapeutics, Senti Biosciences, GenScript and ADARx Pharmaceuticals, among others.
- Headquarter Oxford, United Kingdom
- Employees 102 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Oxford Genetics Ltd
- Date of Incorporation 28 Apr, 2011
- Jurisdiction OXFORD, UNITED KINGDOM
-
Annual Revenue
$110.6 K (USD)-35as on Dec 31, 2023
-
Net Profit
$-43.65 K (USD)-257as on Dec 31, 2023
-
EBITDA
$-42.48 K (USD)-309as on Dec 31, 2023
-
Total Equity Funding
$28.09 M (USD)
in 13 rounds
-
Latest Funding Round
$1.02 M (USD), Series A
Jul 07, 2025
-
Investors
Gov.uk
& 4 more
-
Employee Count
102
as on Dec 31, 2021
-
Acquired by
WuXi AppTec
(Mar 02, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of OXGENE
OXGENE has successfully raised a total of $28.09M across 13 strategic funding rounds. The most recent funding activity was a Series A round of $1.02 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Series A — $1.0M
-
First Round
First Round
(01 Jun 2011)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2025 | Amount | Series A - OXGENE | Valuation |
investors |
|
| May, 2020 | Amount | Series A - OXGENE | Valuation | Mercia , Canaccord Genuity Group |
|
| Mar, 2019 | Amount | Series A - OXGENE | Valuation | Mercia , Canaccord Genuity Group |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in OXGENE
OXGENE has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include Gov.uk, WuXi AppTec and Canaccord Genuity Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment management services are provided by Mercia to various clients.
|
Founded Year | Domain | Location | |
|
Merger and acquisitions advisory firm
|
Founded Year | Domain | Location | |
|
Diversified asset management services are offered globally by Invesco.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by OXGENE
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - OXGENE
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Oxgene Comparisons
Competitors of OXGENE
OXGENE operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inscripta, Poseida Therapeutics, Senti Biosciences, GenScript and ADARx Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Speech recognition solutions are provided by Inscripta for healthcare professionals.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Cell-based therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Reagents and instruments are provided for life sciences research.
|
|
| domain | founded_year | HQ Location |
Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts
|
|
| domain | founded_year | HQ Location |
Genomic and theranostic services for oncology precision medicine are delivered.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Oxgene
Frequently Asked Questions about OXGENE
When was OXGENE founded?
OXGENE was founded in 2011.
Where is OXGENE located?
OXGENE is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Is OXGENE a funded company?
OXGENE is a funded company, having raised a total of $28.09M across 13 funding rounds to date. The company's 1st funding round was a Series A of $8.59M, raised on Jun 01, 2011.
How many employees does OXGENE have?
As of Dec 31, 2021, the latest employee count at OXGENE is 102.
What is the annual revenue of OXGENE?
Annual revenue of OXGENE is $110.6K as on Dec 31, 2023.
What does OXGENE do?
OXGENE was founded in 2011 in Oxford, United Kingdom, and operates in the biotechnology sector. A platform for mammalian cell engineering is offered, along with plasmid and DNA component products and SnapFast plasmid technology. DNA sequences are designed, protein expression is optimized, cell lines are developed, and viral delivery systems are improved. Bioinformatics and gene-editing technologies are integrated to support streamlined workflows for cell line production.
Who are the top competitors of OXGENE?
OXGENE's top competitors include CRISPR Therapeutics, Senti Biosciences and Poseida Therapeutics.
Who are OXGENE's investors?
OXGENE has 5 investors. Key investors include Gov.uk, WuXi AppTec, Canaccord Genuity Group, Mercia, and Invesco.